• Kiyoshi Takahara, Ryosuke Ando, Kent Kanao, Toshiki Ito, Hideaki Miyake, Makoto Sumitomo, Takahiro Yasui, and Ryoichi Shiroki.
• Department of Urology, Fujita Health University, School of Medicine, Toyoake, Japan takahara@fujita-hu.ac.jp.
• Anticancer Res. 2020 Aug 1; 40 (8): 4395-4400.

Background/AimThe therapeutic outcomes of patients with metastatic renal cell carcinoma (mRCC) have dramatically improved with the introduction of molecular-targeted agents. The observational multicenter study was conducted to develop a novel stratification system for the intermediate risk group of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model.Patients And MethodsThe present study included 252 Japanese patients with mRCC who received first-line molecular-targeted therapy at four institutions.ResultsThe 252 patients were classified into the favorable, intermediate, and poor risk groups by the IMDC model. For the intermediate risk group, multivariate analysis of the six factors included in the IMDC model revealed that a low performance status, anemia, and a high platelet count were independent predictors of poor overall survival (OS). The intermediate risk group was subsequently divided into the following two groups (int -group 1 and 2) by the three independent OS predictors. Significant differences in the OS were noted among the IMDC favorable risk group, int-group 1, int-group 2, and poor risk group.ConclusionThe novel stratification presented in this study could be a useful tool for further prognostication of patients with mRCC classified into the intermediate risk group according to the IMDC model after first-line molecular-targeted therapy.Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

27 keywords...

hide…